Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Fukuoka-1 strain of transmissible spongiform encephalopathy agent infects murine bone marrow-derived cells with features of mesenchymal stem cells.

Cervenakova L, Akimov S, Vasilyeva I, Yakovleva O, McKenzie C, Cervenak J, Piccardo P, Asher DM.

Transfusion. 2011 Aug;51(8):1755-68. doi: 10.1111/j.1537-2995.2010.03041.x.

2.

[Biology of non-conventional transmissible agents or prions].

Dormont D.

Rev Neurol (Paris). 1998 Feb;154(2):142-51. Review. French.

PMID:
9773035
3.

Detection of PrP in extraneural tissues.

Brown KL, Ritchie DL, McBride PA, Bruce ME.

Microsc Res Tech. 2000 Jul 1;50(1):40-5. Review.

PMID:
10871547
4.

Are prions transported by plasma exosomes?

Cervenakova L, Saá P, Yakovleva O, Vasilyeva I, de Castro J, Brown P, Dodd R.

Transfus Apher Sci. 2016 Aug;55(1):70-83. doi: 10.1016/j.transci.2016.07.013. Review.

PMID:
27499183
5.

Prion protein and species barriers in the transmissible spongiform encephalopathies.

Priola SA.

Biomed Pharmacother. 1999;53(1):27-33. Review.

PMID:
10221165
6.

The role of host PrP in Transmissible Spongiform Encephalopathies.

Cancellotti E, Barron RM, Bishop MT, Hart P, Wiseman F, Manson JC.

Biochim Biophys Acta. 2007 Jun;1772(6):673-80. Review.

7.

Protein misfolding cyclic amplification (PMCA): Current status and future directions.

Saá P, Cervenakova L.

Virus Res. 2015 Sep 2;207:47-61. doi: 10.1016/j.virusres.2014.11.007. Review.

PMID:
25445341
8.

Prion protein interconversions.

Caughey B.

Philos Trans R Soc Lond B Biol Sci. 2001 Feb 28;356(1406):197-200; discussion 200-2. Review.

9.

A 25 nm virion is the likely cause of transmissible spongiform encephalopathies.

Manuelidis L.

J Cell Biochem. 2007 Mar 1;100(4):897-915. Review.

PMID:
17044041
10.

Prions and their partners in crime.

Caughey B, Baron GS.

Nature. 2006 Oct 19;443(7113):803-10. Review.

PMID:
17051207
11.

Species barriers in prion diseases--brief review.

Moore RA, Vorberg I, Priola SA.

Arch Virol Suppl. 2005;(19):187-202. Review.

PMID:
16355873
12.

Experimental approaches to TSE prevention via inhibition of prion formation.

Politopoulou G.

Protein Pept Lett. 2004 Jun;11(3):249-55. Review.

PMID:
15182226
13.

[Anesthesia and non-conventional transmissible agents (or prion diseases)].

Estèbe JP.

Ann Fr Anesth Reanim. 1997;16(8):955-63. Review. French.

PMID:
9750644
14.

In vitro conversion of normal prion protein into pathologic isoforms.

Bossers A, Rigter A, de Vries R, Smits MA.

Clin Lab Med. 2003 Mar;23(1):227-47. Review.

PMID:
12733434
15.

Cellular aspects of prion replication in vitro.

Grassmann A, Wolf H, Hofmann J, Graham J, Vorberg I.

Viruses. 2013 Jan 22;5(1):374-405. doi: 10.3390/v5010374. Review.

16.

Prion biology relevant to bovine spongiform encephalopathy.

Novakofski J, Brewer MS, Mateus-Pinilla N, Killefer J, McCusker RH.

J Anim Sci. 2005 Jun;83(6):1455-76. Review.

17.

A single amino acid alteration in murine PrP dramatically alters TSE incubation time.

Manson JC, Barron R, Jamieson E, Baybutt H, Tuzi N, McConnell I, Melton D, Hope J, Bostock C.

Arch Virol Suppl. 2000;(16):95-102. Review.

PMID:
11214938
18.

Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions.

Caughey B, Baron GS, Chesebro B, Jeffrey M.

Annu Rev Biochem. 2009;78:177-204. doi: 10.1146/annurev.biochem.78.082907.145410. Review.

19.

Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: A common mechanism for anti-TSE compounds?

Caughey B, Caughey WS, Kocisko DA, Lee KS, Silveira JR, Morrey JD.

Acc Chem Res. 2006 Sep;39(9):646-53. Review.

PMID:
16981681
20.

New in vivo and ex vivo models for the experimental study of sheep scrapie: development and perspectives.

Laude H, Vilette D, Le Dur A, Archer F, Soulier S, Besnard N, Essalmani R, Vilotte JL.

C R Biol. 2002 Jan;325(1):49-57. Review.

PMID:
11862622

Supplemental Content

Support Center